Navigation Links
NYU Cancer Institute experts present at American Society of Clinical Oncology annual meeting
Date:5/21/2010

study was completed in collaboration with two other institutions and research was supported by grants from the American Society of Hematology, St. Baldrick's Foundation, and the National Cancer Institute.


Abstract # 8596: Sunday, June 6th at 8:00 AM in Chicago, IL
Prognostic Relevance of Increased Detection of Lymphovascular Invasion in Primary Melanoma Using D2-40 and CD34 Compared to Routine Histology
Presenter: Farbod Darvishian, MD, assistant professor, Department of Pathology, NYU School of Medicine

Lymphovascular invasion (LVI) in melanoma is the identification of tumor cells within the lymphatic vessels. The presence of melanoma tumor cells inside these vessels has been shown to be associated with poorer patient prognosis. This negative prognostic marker for melanoma patients can sometimes be difficult to detect using routine histology techniques. However, use of immunohistochemical markers such as D2-40 or CD34 can increase the number of cases of LVI identified, but the prognostic relevance of this increased detection has not previously been assessed. In a study of 246 melanoma patients, researchers show that LVI detected using these immunohistochemical markers is a better predictor of outcome than LVI detected by histology alone. Results suggest that in melanoma cases when LVI is reported, the use of D2-40 or CD34 should be considered. Authors conclude, the use of these two special stains that highlight the vessels, help physicians better detect more cases of LVI than with the current histology techniques. The increased number of cases of LVI detected using these stains is clinically relevant, and thus if LVI is reported, pathologists should consider using these markers in addition to the current standard technique.


Abstract # 8553: Sunday, June 6th at 8:00 AM in Chicago, IL
The Use of Integrative Genomics to Define Molecular Signatures of Melanoma Histologic Subtypes
Presenter:
'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Gene fusions may be the smoking gun in prostate cancer development, U-M study finds
2. Study raises new concerns about radiation and breast cancer
3. Slight changes in 2 key genes appear to launch breast cancer development
4. TGen researcher awarded American Cancer Society fellowship
5. Einstein researcher awarded prestigious cancer research grant
6. Cancer: Trapping the escape artist
7. U-M study achieves reduced side effects in head and neck cancer treatment
8. Milk and risk of renal cell cancer: Genetic research sheds new light
9. Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
10. Key mechanism identified in metastatic breast cancer
11. Flaxseed-fed chickens shed light on ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Opening up a new door in synthetic biology, a ... produces a continuous supply of tiny lipid spheres that ... membrane. "Cells are essentially small, complex bioreactors enclosed by ... California, Irvine. "Effectively producing vesicles with lipid membranes that ...
... TEMPE, Ariz. Humans are having an effect on Earth,s ... the warming of the planet we are causing. Now you ... are leaving behind. The only question is how large of ... in the current issue of Science (Dec. 16, ...
... one step closer, thanks to a new twist on an ... Illinois researchers, led by professors Jianjun Cheng and Fei Wang, ... segments to cells. The team published its work in the ... these are new materials that could potentially be used for ...
Cached Biology News:Researchers assess effects of a world awash in nitrogen 2Let's do the twist: Spiral proteins are efficient gene delivery agents 2Let's do the twist: Spiral proteins are efficient gene delivery agents 3
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... Baltimore, MD (PRWEB) November 24, 2014 ... recruiting underrepresented patient populations into clinical trials at ... Maryland. , “Continental was created with the ... trials play a fundamental role in medical advances," ... the Tuskegee syphilis experiment to the immortal cell ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... -- PARIS, September 20, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... a central alternative to petroleum-based energy production. However, current ... yield and is more expensive to mass-produce. In addition, ... on the environment is incomplete, experts say. To ... of solar power, a research team from Rochester Institute ...
... contribution to the accelerated development of new, safe ... in the US and around the world, will ... between Arizona State University and Quintiles ( www.quintiles.com ... is a leader in managing clinical research. ...
Cached Biology Technology:Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 2Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 3Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 4Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 5Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 6Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 7Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 8Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 9Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 10Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 11Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses 12Research team assesses environmental impact of organic solar cells 2Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: